abrdn Life Sciences Investors
HQL
$20.62
$0.412.03%
| Weiss Ratings | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Reward Grade | C | |||
| Risk Index | Fair | |||
| Risk Grade | C- | |||
| Company Info | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Provider | abrdn Inc. | |||
| Manager/Tenure (Years) | Jason C. Akus (2) | |||
| Website | http://www.abrdn.com/us | |||
| Fund Information | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Fund Name | abrdn Life Sciences Investors | |||
| Category | Health | |||
| Sub-Category | Healthcare Sector Equity | |||
| Prospectus Objective | Specialty - Health | |||
| Inception Date | May 08, 1992 | |||
| Open/Closed To New Investors | Open | |||
| Minimum Initial Investment | -- | |||
| Minimum Subsequent Investment | -- | |||
| Front End Fee | -- | |||
| Back End Fee | -- | |||
| Dividends and Shares | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield | 3.93% | |||
| Dividend | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield (Forward) | 0.06% | |||
| Asset Allocation | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash | 2.77% | |||
| Stock | 90.59% | |||
| U.S. Stock | 79.87% | |||
| Non-U.S. Stock | 10.72% | |||
| Bond | 0.00% | |||
| U.S. Bond | 0.00% | |||
| Non-U.S. Bond | 0.00% | |||
| Preferred | 5.65% | |||
| Convertible | 0.20% | |||
| Other Net | 0.79% | |||
| Price History | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 3.91% | |||
| 30-Day Total Return | 1.98% | |||
| 60-Day Total Return | 17.36% | |||
| 90-Day Total Return | 16.64% | |||
| Year to Date Total Return | 29.03% | |||
| 1-Year Total Return | 69.50% | |||
| 2-Year Total Return | 69.31% | |||
| 3-Year Total Return | 100.39% | |||
| 5-Year Total Return | 63.55% | |||
| Price | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Closing Price | -- | |||
| 1-Month Low Price | $19.10 | |||
| 1-Month High Price | $20.83 | |||
| 52-Week Low Price | $13.20 | |||
| 52-Week Low Price (Date) | Aug 06, 2025 | |||
| 52-Week High Price | $20.83 | |||
| 52-Week High Price (Date) | Jul 09, 2026 | |||
| NAV | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Nav | $22.12 | |||
| 1-Month Low NAV | $21.36 | |||
| 1-Month High NAV | $23.50 | |||
| 52-Week Low NAV | $14.68 | |||
| 52-Week Low NAV (Date) | Aug 11, 2025 | |||
| 52-Week High NAV | $23.50 | |||
| 52-Week High Price (Date) | Jul 09, 2026 | |||
| Beta / Standard Deviation | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.97 | |||
| Standard Deviation | 18.95 | |||
| Balance Sheet | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Total Assets | 662.20M | |||
| Operating Ratios | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Expense Ratio | 1.35% | |||
| Turnover Ratio | 73.00% | |||
| Performance | HQL-NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Last Bull Market Total Return | 45.72% | |||
| Last Bear Market Total Return | -8.89% | |||